Dupilumab versus tralokinumab in atopic dermatitis: A propensity score-adjusted comparison from BioDay
Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry
Topical Steroid Withdrawal: Perspectives of Dutch Healthcare Professionals
Treatment goals and preferences of pediatric atopic dermatitis patients, young adults, and caregivers
Complementary Analysis of Local and Systemic Effects of Dupilumab in Paediatric AD Using Tape Strips and Serum
Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results
Dupilumab-Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry
Ocular surface disease in pediatric patients with moderate-to-severe atopic dermatitis
van der Rijst & Velduis, et al.
Pubmed
Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
Type 2 Immune-Dominant Endotype Is Not Associated With Increased Responsiveness to Dupilumab Treatment in Adult Atopic Dermatitis Patients
Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis
Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients
Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry
Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation
Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis
Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps
IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval
Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry
Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab
Dupilumab-associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response, and conjunctival goblet cell analysis
Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series
Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis
Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease
Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry
The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis
Ocular surface disease is common in moderate-to-severe atopic dermatitis patients
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.
Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry.
Early and long-term effects of dupilumab treatment on circulating T-cell functions in moderate-to-severe atopic dermatitis patients.
EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
Dupilumab shows long-term effectiveness in a large cohort of difficult-to-treat atopic dermatitis patients in daily practice: 52-week results from the Dutch BioDay registry.
Two-year Drug Survival of Dupilumab in a Large Cohort of Difficult-To-Treat Adult Atopic Dermatitis Patients Compared to Cyclosporine A and Methotrexate: Results From the BioDay Registry
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Dupilumab facial redness: Positive effect of itraconazole.
Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study.
Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.
